AstraZeneca Pharma India has voluntarily surrendered the marketing authorisation for its prostate cancer drug Olaparib ...

AstraZeneca Pharma India has surrendered marketing authorization for Olaparib (Lynparza) in India due to commercial reasons. The drug is indicated for metastatic castration-resistant prostate cancer.

In a live virtual event, Thomas C. Krivak, MD, reviewed the key studies of PARP inhibitor and bevacizumab maintenance in ...

Jacquie Beltrao was diagnosed with incurable stage four breast cancer in 2020 but, following chemotherapy and a mastectomy, ...

Olaparib, an inhibitor of poly (ADP-ribose) polymerase (PARP), has demonstrated promising outcomes in treating HER2-negative early-stage breast cancer with BRCA mutations. However, a comprehensive ...

Patients in the pembrolizumab-olaparib arm had clinically meaningful improvements in PFS over patients in the control arm.

Bangalore: AstraZeneca Pharma India Limited has surrendered its marketing authorisation for Olaparib film-coated tablets 100mg and 150mg (Lynparza) for indication in combination with ...

Niraparib maintenance has a tolerable safety profile in patients with ovarian cancer, with hematologic toxicities being “the primary concern,” according to researchers. They e ...

Sky News presenter Jacquie Beltrao has provided her followers with an update on her battle against stage four cancer. The ...

Jacquie Beltrao had an incredible recovery from stage four cancer after testing out a miracle drug in 2020 and has taken to ...